Phase II Study of BKM120 in Men With Metastatic Castration-Resistant Prostate Cancer.

Trial Profile

Phase II Study of BKM120 in Men With Metastatic Castration-Resistant Prostate Cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Buparlisib (Primary) ; Enzalutamide
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Aug 2017 According to results published in the European Journal of Cancer, concurrent buparlisib and enzalutamide at 160 mg once daily was permitted through a protocol amendment in order to test the efficacy of combined pathway inhibition in men with mCRPC progressing on enzalutamide, the use of concurrent enzalutamide was not randomized but rather offered to patients progressing on enzalutamide at entry.
    • 01 Aug 2017 Results published in the European Journal of Cancer.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top